Join Immix Biopharma and key opinion leaders Heather Landau, MD (NEXICART-2 Principal Investigator, Director of Amyloidosis Program, Memorial Sloan-Kettering Cancer Center), Shahzad Raza, MD (Cleveland Clinic leader of AL Amyloidosis program), and Vaishali Sanchorawala, MD (Professor, Boston University School of Medicine) to discuss the significance of Phase 2 clinical results from IMMX’s NEXICART-2 study of cell therapy NXC-201 in relapsed/refractory amyloidosis, selected for an oral presentation at ASH 2025, and the evolving treatment landscape for relapsed/refractory AL Amyloidosis.